Program overview
Context
Indication: EGFR-mutant Non-small Cell Lung Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Low Signal
Sacituzumab Tirumotecan and Limertinib
Sacituzumab Tirumotecan and Limertinib is flagged as low signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 0/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07323056
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07323056 | Low Signal (RECRUITING) | None | Low Signal | rare_population_signal | strict_eligibility_signal |